MYGN
Myriad Genetics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MYGN
Myriad Genetics, Inc.
A leader in genetic testing and precision medicine
Biological Technology
Invalid Date
10/06/1995
NASDAQ Stock Exchange
2700
12-31
Common stock
322 North 2200 West, Salt Lake City, UT 84116
--
Myriad Genetics, Inc., is a Delaware corporation. The company is a leading genetic testing and precision medicine company dedicated to promoting the health and well-being of all people. The company provides insights that help people take control of their health and enable health care providers to better detect, treat and prevent disease. The company develops and provides tests that help assess the risk of disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs.
Company Financials
EPS
MYGN has released its 2024 Q4 earnings. EPS was reported at 0.03, versus the expected 0.03, meeting expectations. The chart below visualizes how MYGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MYGN has released its 2024 Q4 earnings report, with revenue of 210.60M, reflecting a YoY change of 7.12%, and net profit of -42.50M, showing a YoY change of -36.22%. The Sankey diagram below clearly presents MYGN’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
